Just like the 2020 resolution, Novartis AG’s $twenty five million 2016 civil resolution Along with the SEC worried poor sponsorships of HCPs to conferences and inappropriate payments to HCPs to gather “health-related data.” The reality that Novartis is now experiencing a substantially larger—and felony—resolution for related misconduct ne